Laboratory of Precision and Nanomedicine develops smart cancer therapeutics with increased potency and decreased side effects.
Our mission is to change the perception of cancer as being a largely incurable disease. We use in vivo peptide phage display screens to identify homing peptides that bind to specific targets in the vasculature. Corresponding synthetic peptides are explored for targeting drugs, biologicals, and nanoparticles into tumors to increase their therapeutic index. We focus on development of novel diagnostic tests and therapeutics for the early detection and precision treatment of solid tumors (glioblastoma, and breast, prostate ovarian, prostate, and colorectal carcinoma). Our lab is also at the forefront of development of next generation peptidic shuttles capable of efficient and high capacity payload delivery across the blood brain barrier.
Success with our Estonian Research Council project "Precision targeting of infiltrative glioblastoma"
Written on Monday, 26 December 2022 01:47We are delighted to announce positive funding decision by the Estonian Research Council on our 5-year research project "Precision targeting of infiltrative glioblastoma". The project…
Prof. Erkki Ruoslahti conferred the degree of Honorary Doctor of Biomedicine of UniTartu
Written on Monday, 26 December 2022 01:32Disntinguished professor Erkki Ruoslahti, a longtime mentor and present collaborator of Prof. Teesalu, has been conferred the degree of Honorary Doctor of Biomedicine of the…
Adipose tissue identified as a frequent extrapulmonary site for SARS-CoV-2
Written on Monday, 26 December 2022 01:11The C-end Rule peptides, codiscovered by Prof. Tambet Teesalu, have emerged as important targeting and cellular entry elements for many viruses, including SARS-CoV-2. Our group…
Paclitaxel-Loaded Cationic Fluid Lipid Nanodiscs and Liposomes with Brush-Conformation PEG Chains Penetrate Breast Tumors and Trigger Caspase-3 Activation.
Written on Monday, 26 December 2022 02:17Simón-Gracia L, Scodeller P, Fisher WS, Sidorenko V, Steffes VM, Ewert KK, Safinya CR, Teesalu T. ACS Appl Mater Interfaces. 2022 Dec 15. doi: 10.1021/acsami.2c17961.…
SARS-CoV-2 infects adipose tissue in a fat depot- and viral lineage-dependent manner.
Written on Monday, 26 December 2022 02:16Saccon TD, Mousovich-Neto F, Ludwig RG, Carregari VC, Dos Anjos Souza AB, Dos Passos ASC, Martini MC, Barbosa PP, de Souza GF, Muraro SP, Forato…
OctoberPeptide targeted polymersomes bind to M2 human macrophagesPolymersomes targeted with an M2 macrophage binding peptide (green) identified in our lab using phage display bind to and are taken up by M2s (red) originated from human primary monocytes.…
SeptemberPolymersomes targeted with an M2 macrophage binding peptide in a mouse model of triple negative breast cancerPolymersomes targeted with an M2 macrophage binding peptide (green) identified in our lab using phage display home to M2 TAMs (red) after intravenous administration in a mouse model of triple…
JanuaryHigh infiltration of CD206+ cells in human breast tumorsImmunohistochemical staining of human CD206 (brown) with nuclear counterstain (Hematoxilin, in dark blue). Authors: Anni Lepland and Pablo Scodeller.